|
| 37400321 | Role of FDG PET/CT in Management of Patients with Prostate Cancer. | Semin Nucl Med | 2024 |
| 37147359 | PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. | Prostate Cancer Prostatic Dis | 2024 |
| 36029329 | Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer. | World J Urol | 2023 |
| 37490642 | Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer. | JCO Clin Cancer Inform | 2023 |
| 37549632 | BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. | EBioMedicine | 2023 |
| 37498948 | Is genetic testing coming of age in advanced prostate cancer? | BJU Int | 2023 |
| 37323189 | Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review. | Ther Adv Med Oncol | 2023 |
| 37323184 | Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. | Ther Adv Med Oncol | 2023 |
| 37285865 | Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 37179240 | The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. | Eur Urol | 2023 |
| 37168818 | NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. | Contemp Clin Trials Commun | 2023 |
| 36541133 | Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter? | Expert Rev Pharmacoecon Outcomes Res | 2023 |
| 36509970 | Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? | Nat Rev Urol | 2023 |
| 36411180 | Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis. | Urol Oncol | 2023 |
| 36043882 | Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 |
| 34326127 | <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. | J Nucl Med | 2022 |
| 35507017 | A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. | Clin Cancer Res | 2022 |
| 35675470 | The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. | Prostate | 2022 |
| 35420921 | Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. | J Clin Oncol | 2022 |
| 35849697 | Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities. | Curr Opin Urol | 2022 |
| 36465905 | AlphaBet: Combination of Radium-223 and [<sup>17</sup> <sup>7</sup>Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). | Front Med (Lausanne) | 2022 |
| 36524004 | Editorial: Prostate cancer genomics: Application at different stages of a patient's journey. | Front Oncol | 2022 |
| 35868978 | Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer? | Eur Urol Oncol | 2022 |
| 36332623 | KIT as a therapeutic target in neuroendocrine prostate cancer. | Cancer Cell | 2022 |
| 35993979 | Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer. | Crit Rev Oncog | 2022 |
| 36239736 | Systemic therapy in metastatic hormone-sensitive prostate cancer. | Curr Opin Support Palliat Care | 2022 |
| 36261050 | PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 35950899 | Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. | Future Oncol | 2022 |
| 36185587 | Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma. | Eur Urol Open Sci | 2022 |
| 36183329 | Modern paradigms for prostate cancer detection and management. | Med J Aust | 2022 |
| 33710759 | Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. | Intern Med J | 2022 |
| 35158771 | Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. | Cancers (Basel) | 2022 |
| 35098653 | Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. | Asia Pac J Clin Oncol | 2022 |
| 35034502 | A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. | Future Oncol | 2022 |
| 35331214 | Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. | BMC Med | 2022 |
| 35080190 | Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. | Future Oncol | 2022 |
| 34493414 | Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. | Eur Urol | 2022 |
| 34724226 | Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. | Int J Cancer | 2022 |
| 34420037 | Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. | Prostate Cancer Prostatic Dis | 2022 |
| 34161628 | <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. | Asia Pac J Clin Oncol | 2022 |
| 31103601 | Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. | Eur Urol Focus | 2021 |
| 35492221 | Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. | BJUI Compass | 2021 |
| 33573754 | Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic. | Clin Lymphoma Myeloma Leuk | 2021 |
| 33682320 | UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). | BJU Int | 2021 |
| 33490707 | A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. | Contemp Clin Trials Commun | 2021 |
| 33863648 | Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. | Clin Genitourin Cancer | 2021 |
| 33836265 | Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. | Ann Oncol | 2021 |
| 33746214 | Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 34434533 | Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer. | J Extracell Vesicles | 2021 |
| 34638448 | Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 |